ClinicalTrials.gg

Program

efdoralprin alfa

A development code. Also written as “SAR447537”.

In Sanofi’s pipeline, AAT fusion protein. Its studies are mostly in alpha 1-Antitrypsin Deficiency, led by Sanofi.

Furthest: phase 2, since Mar 28, 20232 company-led studies, 1 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi21 open or runningphase 2since Mar 28, 2023Mar 28, 2023Jun 30, 2028phase 2 · NCT05897424
  • Named in Sanofi’s own pipeline as efdoralprin alfa, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 28, 2023First study: phase 2 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT05856331 · 99 enrolled · United States, Australia, Denmark and more
  2. May 31, 2023Phase 2 study in alpha 1-Antitrypsin DeficiencyNCT05897424 · 185 enrolled · United States, Australia, Denmark and more

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in alpha 1-Antitrypsin DeficiencyNCT05897424

TargetBeta

“AAT fusion protein”the company's pipeline, read by Claude · source
“Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Defic…”study text, read by Claude · the study

Other programs on SERPINA1

ProgramCompanyFurthest phaseStudies
ensitrelvirruleShionogiphase 35
CTX460rulecrispr-therapeuticsphase 21
Proteasome Inhibitor SHY-ONC6ruleshy-therapeuticsphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05897424alpha 1-Antitrypsin Deficiency · United States, Australia, Denmark and more2Active, not recruitingJun 30, 2028185
NCT05856331alpha 1-Antitrypsin Deficiency · United States, Australia, Denmark and more2CompletedAug 6, 202599

How it is read

Names in the registry

  • “SAR447537”, 2 entries

Codes read as this program: SAR447537.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.